Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Pfizer (PFE), GlaxoSmithKline Company ViiV Healthcare Announces SWORD 100-Week Data for Juluca (dolutegravir/rilpivirine) at AIDS 2018July 24, 2018 5:54 AM Pfizer (PFE), GlaxoSmithKline Company ViiV Healthcare Highlights Phase III Data at AIDS 2018July 24, 2018 5:49 AM Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid TumorsJuly 23, 2018 7:30 AM